Bustamante: #AGBTph18 Shows May '18 GenomeWeb - Color and FH Foundation https://t.co/qMrKnZ7bGT
9:07pm September 6th 2018 via Twitter Web Client
Bustamante: #AGBTph18 63% of high-risk FH pts cannot get approval. Goes through flowchart, lipid clinic n=20,434; FH-pos n=582
9:04pm September 6th 2018 via Twitter Web Client
Bustamante: #AGBTph18 Top 20% takes up 81.2% of the budget. 70% via employer.
9:03pm September 6th 2018 via Twitter Web Client
Bustamante: #AGBTph18 '06 NEJM https://t.co/ClUS3vkb6H Problem: Repatha is $12K/yr. '$500B increase'. Per-capita - in '10 $8.4K
9:02pm September 6th 2018 via Twitter Web Client
Bustamante: #AGBTph18 Familial hypercholesterolemia (FH) most common genetic cause of heart disease; affects 1/250;… https://t.co/oU1IVlUKYN
8:58pm September 6th 2018 via Twitter Web Client
Bustamante: #AGBTph18 How will genomics become a tool in population mgmt? How is benefit distributed across ethnic… https://t.co/JpD8Kiuxmk
8:56pm September 6th 2018 via Twitter Web Client
Bustamante: #AGBTph18 Biomedical science is 'emerging'; as chair of a new dept, methods and learning from biomedica… https://t.co/p2bFfBaOT0
Carlos Bustamante (Stanford Univ) #AGBTph18 Healthcare delivery as a supply chain problem: The role of genomics and… https://t.co/EH2GwlTs6W
8:53pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 3 Nobels for cholesterol; all before statins approved etc. Length of time to benefit pts - the goal is to speed it up
8:39pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Triple combo Rx have potential to benefit 'up to 90%'. Learned how to speed-up process, expande… https://t.co/MELMbBFqz6
8:36pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Three novel MOA's in order to boost function; 3.5y ago, decided to try a triple combo. Shows 2… https://t.co/9pftZghqW0
8:32pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Two different medicines developed at Aurora: '11 ref https://t.co/CXatqCVfmw Shows PhIII results https://t.co/qR5sLlNI2r
8:30pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 F508del mut: protein processing defect - doesn't get to cell surface, and then a gating defect.… https://t.co/H02RrqqC1C
8:28pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 50% reduction in death, long-term, real-world data for Ivacaftor. Problem: only a 10% fraction w/spec mutation
8:27pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Shows data from a '12 database with n=27,804. 2% per year decline. Now: 47% decrease in rate of… https://t.co/u9visK7bWX
Altshuler #AGBTph18 Ivacaftor's mechanism; G511D causes defect in channel gating activity of CFTR, and ivacaftor opens it up.
8:24pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 '89 Science https://t.co/vYSHUF1CQY Lodish quote: "I wouldn't bother" w/small molecule approach
8:22pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 50y of helping people with CF; 75K in NA, EU and AUS. Median age of death in mid-20's. Allelic… https://t.co/nyDAIXI4iv
8:20pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Points to this '13 ref https://t.co/i1PvyDBclW and each author w/in 3 y in industry to help on the road less travelled
8:19pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Candidate attrition occurs 75% of PhII candidates fail from PhII to PhIII, mainly to 'lack of e… https://t.co/hHVTRqsgNF
8:17pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Lays out the difficulty: the need to discover 13-15 clinical candidates, and work through all t… https://t.co/OEmiQUR9Nk
8:16pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Most cases 'the biology will be new' and thus need to discover and develop innovative medicines.
8:15pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Mendelian diseases ('86 on) and genetic diseases ('07 on) set the stage for precision medicine.… https://t.co/83198dbs7G
8:14pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Ivacaftor synthesized in '04, approved w/Lumacaftor in '15. A 20-year journey. '07 Lumacaftor candidate ID'd '07
8:12pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Presents a timeline of CF: '89 gene discovered; function in the '90's; in '99 Aurora/Vertex SD starts work.
8:11pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Points out Bill, from 2015 at the White House SOTU address, in medical school, and a CF pt. on a Vertex drug
8:10pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Scientists' dedication is 'on-par w/academia, but no one knows who they are'. Rx 'magically appears'.
8:09pm September 6th 2018 via Twitter Web Client
Altshuler #AGBTph18 Second title: Humanizing drug discoery. Human genetics/genomics is 'unmatched at getting at human biology'.
8:08pm September 6th 2018 via Twitter Web Client
David Altshuler (CSO Vertex) Diverse perspectives on Genomic Medicine #AGBTph18
8:07pm September 6th 2018 via Twitter Web Client
Eric Green, director of NHGRI giving the #AGBTph18 introduction. https://t.co/YPntDtqCdb
8:03pm September 6th 2018 via Twitter for iPhone
Quantapore Working Towards Commercialization of Optical Nanopore Sequencing Tech | GenomeWeb ($) https://t.co/vqTRSdBycL
11:36am September 5th 2018 via Hootsuite Inc.
Radical open-access plan could spell end to journal subscriptions | Nature https://t.co/AEMimT6z4b
10:40am September 5th 2018 via Hootsuite Inc.
New post: Two Pore Guys single-molecule diagnostic platform update https://t.co/vprvahIYGC
12:08pm September 4th 2018 via WP to TWTR on Yuzuki.org
